生物标志物 生物标志物
Michalis Kassinopoulos1, Aldana Lizarraga1, Mahnaz Shekari1
1Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
概括
区域同质性 (ReHo) 可以预测早期阿尔茨海默病的粉样蛋白变化,提供一个潜在的生物标志物,以及氧糖正子发射断层扫描 (FDG-PET). 这项研究探讨了ReHo在临床前阿尔茨海默病的临床实用性.
科学领域:
- 神经成像是一种神经成像.
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 区域同质性 (ReHo) 测量了静止状态功能性MRI (rs-fMRI) 中的血液氧气水平依赖 (BOLD) 信号连贯性.
- ReHo反映了大脑活动和氧气消耗,类似于FDG-PET.
- 预测阿尔茨海默病 (AD) 病理学的ReHo的临床实用性仍然在很大程度上未被探索.
研究的目的:
- 评估使用ReHo来预测AD高风险的认知不受损个体中的粉样沉积变化的可行性.
- 为了比较ReHo与FDG-PET在识别早期AD相关变化的表现.
主要方法:
- 330名没有认知障碍的人接受了rs-fMRI,FDG-PET,Aβ-PET和CSF分析 (Aβ42/40,p-tau181).
- 提取了ReHo和FDG测量值,并与氨基酸负载的基线和纵向变化相关联.
- 统计模型根据年龄,性别,APOE状态,教育程度和p-tau181.1.进行了调整.
主要成果:
- 在截面上,较低的ReHo与较低的CSFAβ42/40相关,而FDG与粉样蛋白没有显著的关联.
- 从长度上看,较低的基线FDG预测随着时间的推移增加了PET粉样蛋白负担.
- 较高的基线ReHo预测,随着时间的推移,CSFAβ42/40的下降.
结论:
- 基线ReHo和FDG提供了关于临床前AD中的粉样蛋白动态的补充信息.
- ReHo证明了作为可溶性粉胺β (Aβ) 早期变化的预测生物标志物的潜力.
- 需要进一步的研究来探索ReHo与AD中的FDG-PET一起的临床实用性.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516